PHRRF — Pharmather Holdings Share News
0.000.00%
Last trade - 00:00Brief: Pharmather Provides Update On Product Pipeline
Brief: Pharmather Applies For FDA Orphan Drug Designation For Ketamine To Treat Rare Neurological Disorder Status Epilepticus
Brief: Pharmather Announces Positive Research Results For Psilocybin Microneedle Patch
Brief: Revive Therapeutics Enters Into Research Collaboration Agreement With Pharmather
Brief: Pharmather Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
Brief: Pharmather Initiates Phase 2 Clinical Trial Of Ketamine For The Treatment Of Parkinson’s Disease
Brief: PharmaTher Announces FDA Approval Of Ketamine IND In Treatment Of Parkinson's Disease
Brief: Pharmather Announces Submission Of IND Application With FDA For Phase 2 Clinical Trial Evaluating Ketamine In Treatment Of Parkinson’s Disease
Brief: Pharmather Files FDA Pre-Ind Meeting Request For Ketamine In Parkinson’S Disease
Brief: Pharmather Announces Exclusive License Agreement With The University Of Arizona For The Commercialization Of Ketamine